Oligomerix, Inc.

Merck Sharp + Dohme Corp.

University of Pennsylvania

Yale University

Msd R&d (China) Co., Ltd.

Kleo Pharmaceuticals, Inc.

Msd R&d Co., Ltd.

H Marie Loughran

Allen B Reitz

Charles Gluchowski

Mark E McDonnell

Haiyan Bian

Eliot J Davidowitz

James G Moe

James Hendrix

Albert S Yehaskel

Michael P Dwyer

Bin Hu

John A McCauley

Peter D Williams

Sherman Tim Waddell

Gregori J Morriello

Xin-Jie Chu

Kartik M Keertikar

Christopher James Bungard

M Katharine Holloway

Lehua Chang

David Jonathan Bennett

Tao Ji

Bin Zhong

Catherine M Wiscount

Jay Edward Wrobel

Dong-Ming Shen

David Spiegel

Jeffrey Claude Pelletier

Nicolas Zorn

Matthew Welsch

Edward C Sherer

Alejandro Crespo

Satyanarayana Tummanapalli

Jesse J Manikowski

Ronald N Harty

Vijayasaradhi Sivalenka

Jessie J Manikowski

Jurgen Schultz

Bruce D Freedman

Jurgen Schulz

John A Mccauley

M Katherine Holloway

Tummanapalli Satyanarayana

Sivalenka Vijayasaradhi

Novel benzofurans, benzothiophenes and indoles useful as inhibitors of tau oligomer formation, useful for the treatment of neurodegenerative diseases and related conditions are disclosed. The invention also relates to the pharmaceutically acceptable salts of said compounds, processes for the preparation of said compounds, intermediates used in the preparation of said compounds, and pharmaceutical compositions containing said compounds. The invention further relates to methods of use of said compounds, salts of said compounds, and said compositions in treating neurodegenerative diseases and related conditions.

Benzofuran, benzothiophene, and indole analogs that inhibit the formation of tau oligomers and their method of use

Novel quinazolinones useful as inhibitors of tau oligomer formation, useful for the treatment of neurodegenerative diseases and related conditions are disclosed. The invention also relates to the pharmaceutically acceptable salts of said compounds, processes for the preparation of said compounds, intermediates used in the preparation of said compounds, and pharmaceutical compositions containing said compounds. The invention further relates to methods of use of said compounds, salts of said compounds, and said compositions in treating neurodegenerative diseases and related conditions.

Quinazolinones that inhibit the formation of tau oligomers and their method of use

The present invention relates to chimeric (including bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic and other cancers where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds bind to the urokinase-type plasminogen activator receptor (uPAR) on the surface of a cancer cell, including a metastatic cancer cell, and consequently recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) against a large number and variety of cancers, thus providing cancer cell death and an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer.

Antibody-recruiting molecules for the treatment of cancer

The present invention includes compounds that are useful in preventing or treating viral infections, such as viral infections caused by a filovirus, arenavirus, rhabdovirus, paramyxovirus, and/or retrovirus. The present invention further includes compositions comprising such compounds, and methods of treating a viral infection in a subject using such compounds.

Antiviral compounds and methods using same

The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. 

Piperazine derivatives as HIV protease inhibitors

The present invention is directed to piperazine derivatives, pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.

Growing community of inventors

Perkasie, PA, United States of America

H Marie Loughran